Neuland Laboratories Limited vs Jubilant Pharmova Limited
An objective side-by-side of NEULANDLAB and JUBLPHARMA, both in Pharmaceuticals - Indian - Bulk Drugs: valuation, profitability, growth, balance sheet, ownership and share-price performance. Where one number is clearly better on its own terms (lower P/E, higher ROE), it is shaded. That is a description, not a recommendation.
Prices as of 2026-11-05 close
Latest results: NEULANDLAB Sep 2026 · JUBLPHARMA Jun 2026
At a glance
- Neuland Laboratories Limited is the larger company by market value, about 1.7 times the size of Jubilant Pharmova Limited.
- On trailing earnings, Jubilant Pharmova Limited trades at the lower P/E (42.7 against 56.0).
- Neuland Laboratories Limited earns the higher return on equity (22.3% against 5.0%).
- Over three years Jubilant Pharmova Limited has grown profits faster (47% a year against 30%).
- Over the past year the share prices returned +22.4% (NEULANDLAB) and -15.3% (JUBLPHARMA).
| Metric | Neuland Laboratories NEULANDLAB |
Jubilant Pharmova JUBLPHARMA |
|---|---|---|
| Size and price | ||
| Market cap | ₹25,381 Cr | ₹15,002 Cr |
| Share price | ₹19,783.00 | ₹947.05 |
| Valuation | ||
| P/E | 55.99 | 42.69 |
| P/B | 12.50 | 2.12 |
| EV/EBITDA | 36.52 | 15.30 |
| PEG | 1.87 | 0.91 |
| Dividend yield | 0.2% | 0.5% |
| Profitability | ||
| ROE | 22.3% | 5.0% |
| ROCE | 27.0% | 9.0% |
| Operating margin | 30.5% | 14.1% |
| Sales (TTM) | ₹2,307 Cr | ₹8,607 Cr |
| Net profit (TTM) | ₹453 Cr | ₹351 Cr |
| Growth | ||
| Latest quarter sales YoY | -12.6% | +1385.3% |
| Latest quarter profit YoY | -46.7% | +3217.6% |
| Sales CAGR 3Y | +19.0% | +10.0% |
| Profit CAGR 3Y | +30.0% | +47.0% |
| Sales CAGR 5Y | +17.0% | +6.0% |
| Profit CAGR 5Y | +39.0% | -13.0% |
| Financial strength | ||
| Debt/Equity | 0.17 | 0.51 |
| Interest cover | 20.14 | 2.51 |
| Ownership | ||
| Promoter holding | 32.3% | 47.7% |
| Promoter change (4 qtrs) | -0.38 pp | +0.01 pp |
| Price performance | ||
| Return 1M | -9.69% | -4.26% |
| Return 3M | -0.87% | +2.42% |
| Return 1Y | +22.43% | -15.32% |
| Return YTD | +30.37% | -11.76% |
| Technical condition | ||
| Technical score | 46 | 63 |
| RS rating (1-99) | 82.00 | 60.00 |
| % vs 200-DMA | +13.05% | +0.39% |
| RSI (14) | 44.37 | 47.70 |
| % from 52-week high | -18.34% | -19.95% |
